来自MSN2 个月
Faricimab lacks proof of added benefit over comparator therapies for macular edema
S ince July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and ...
pharmaphorum2 天
Roche targets wet AMD with faricimab and its 16-week regimen
Faricimab is a bispecific antibody that targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditions ...
New drug means thousands at risk of blindness won't need injections
The medication, faricimab, will be offered to patients being treated for advanced retinal vein occlusion (RVO). It is ...